VANCOUVER, British Columbia — October 9, 2025 — Leads & Copy —Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), has appointed Dr. Joel Gagnier as Chief Science Officer (CSO). The company said the move underscores its commitment to scientific standards and transformative health solutions, enabling AI-driven advancements in musculoskeletal health and pain management.
Dr. Gagnier brings academic and clinical epidemiology leadership to the role. He holds a Doctor of Naturopathic Medicine, an MSc and PhD in Clinical Epidemiology & Biostatistics, and has served as Associate Professor at Western University’s Schulich School of Medicine & Dentistry. He has also trained health researchers as Field Leader of the Clinical Epidemiology & Research Management master’s program.
An expert in clinical trial methodology and outcome measurement, Dr. Gagnier has focused on enhancing health outcome scales and improving trial reporting consistency. His experience aligns with Fifty1 AI Labs’ focus on musculoskeletal conditions, perioperative outcomes, sports medicine, and peptides.
Dr. Gagnier has secured over CAD $20 million in research grants, published more than 210 peer-reviewed papers, and held leadership roles in scientific governance. He has also served as Senior Science Officer at Jamieson Laboratories Ltd. and Chief Scientific Officer at Second Life Global, as well as scientific consultant to global pharma leaders like Sanofi and Johnson & Johnson.
Paul Arora, CEO of Fifty1 AI Labs Inc., said Dr. Gagnier’s expertise will propel the company’s mission to revolutionize wellness through data-driven innovations.
Dr. Joel Gagnier said he looks forward to driving scientific excellence that translates into real-world impact for individuals seeking optimized health outcomes.
Contact:
Investor Relations
Fifty1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
Source: Fifty1 AI Labs, Inc.
